Efficacy and safety of short-acting β-blockers in patients with sepsis-associated cardiac dysfunction: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

The role of ultra-rapid β-blockers in sepsis-associated cardiac dysfunction remains controversial, with conflicting evidence regarding mortality benefits and safety concerns in hemodynamically unstable patients.

Methods

This study retrieved relevant reports on randomized controlled trials of ultra-rapid β-blockers conducted for adult patients with sepsis-associated cardiac dysfunction, up to and including the date of May 30, 2025, from the databases of PubMed, Web of Science, Cochrane Library and Embase. Primary outcomes were 28-day mortality and adverse events; secondary outcomes included heart rate control and mean arterial pressure (MAP) at 48 h. Random-effects models calculated risk ratios (RR) or standardized mean differences (SMD) with 95% confidence interva

SUBMITTER: Zheng M 

PROVIDER: S-EPMC12454437 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature